FASTK

Across TCGA pan-cancer cohorts, FASTK Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FASTK data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FASTK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FASTK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, LGG, and ESCA are the cancer types where FASTK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
LGG	DFS	Median	All	0.089	0.845	<.001	6	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
UCEC	OS	Median	All	1.000	0.666	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FASTK–SCLC (OS)

Open the SCLC breakdown →